PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1299130 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.0%
TTM net income YoY75.0%
TTM EPS YoY81.2%
Revenue 3-yr CAGR2.9%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-83.5%
Net margin-82.5%
FCF margin-77.5%
EBITDA margin-77.4%
Returns
ROE-929.3%
ROA-16.7%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets104.4%
Debt / equity—
Current ratio4.92x
Interest coverage-18.15x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $160.00M | $154.01M |
| Cost of revenue | $114.22M | $116.73M |
| Gross profit | $45.78M | $37.28M |
| R&D expense | $97.31M | $134.92M |
| SG&A expense | $141.49M | $175.02M |
| Operating income | -$553.86M | -$474.31M |
| Interest expense | $6.95M | $13.41M |
| Pretax income | -$546.06M | -$309.54M |
| Income tax | $318,000 | $316,000 |
| Net income | -$546.38M | -$309.85M |
| EBITDA | -$540.87M | -$460.54M |
| EPS (basic) | -1.82 | -1.13 |
| EPS (diluted) | -1.82 | -1.59 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 299.96M | 288.37M |
| Balance sheet | ||
| Cash & equivalents | $63.71M | $57.59M |
| Short-term investments | $215.80M | $334.56M |
| Receivables | $35.45M | $27.52M |
| Inventory | $49.28M | $58.76M |
| Current assets | $375.05M | $495.68M |
| PP&E, net | $24.15M | $30.50M |
| Goodwill | $317.76M | $317.76M |
| Intangibles | $15.12M | $389.57M |
| Total assets | $784.08M | $1.26B |
| Current liabilities | $72.83M | $66.30M |
| Short-term debt | — | $0 |
| Total liabilities | $778.73M | $753.85M |
| Shareholders' equity | $5.35M | $506.59M |
| Shares outstanding | 301.96M | 294.42M |
| Cash flow statement | ||
| Operating cash flow | -$111.21M | -$206.06M |
| Capital expenditure | $2.71M | $6.19M |
| Free cash flow | -$113.92M | -$212.25M |
| Investing cash flow | $115.45M | $124.00M |
| Financing cash flow | $3.43M | -$42.99M |
| Depreciation & amortization | $12.99M | $13.77M |
| Stock-based compensation | $41.67M | $71.04M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.